S-OA-C
Oral Abstracts - Session C - Pediatric Disorders

Track: BMT Tandem "Scientific" Meeting
Wednesday, February 26, 2014: 4:45 PM-6:45 PM
Texas C (Gaylord Texan)
Chairs:
Kimberly A. Kasow, DO and Adriana Seber, MD

Disclosures:
K. A. Kasow, Nothing To Disclose

A. Seber, Nothing To Disclose

81
Exposure of Thymoglobulin Is Associated with Overall Survival in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival
R. Admiraal, MD, Leiden University Medical Center; Cornelia M Jol-van der Zijde, Leiden University Medical Center; Charlotte van Kesteren, PharmD, PhD, University Medical Center Utrecht; Maarten van Tol, PhD, Leiden University Medical Center; Catherijne AJ Knibbe, PharmD, PhD, Leiden Academic Centre for Drug Research; Robbert Bredius, MD, PhD, Leiden University Medical Center; Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht

82
Predictors of Long-Term Clinical Outcome in Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: An International Study
Mieke Aldenhoven, MD, University Medical Center Utrecht; Paul Orchard, MD, University of Minnesota; Joanne Kurtzberg, MD, Duke University Medical Center; Robert Wynn, MD, Royal Manchester Children's Hospital; Anne O'Meara, MD, Our Lady's Hospital for Sick Children; Paul Veys, MD, Great Ormond Street Hospital for Children; Alain Fischer, MD, PhD, Hôpital Universitaire Necker-Enfants Malades; Vassili Valayannopoulos, MD, Hôpital Universitaire Necker-Enfants Malades; Benedicte Neven, MD, PhD, Hôpital Universitaire Necker-Enfants Malades; Attilio Rovelli, MD, San Gerardo University Hospital; Vinod K. Prasad, MD, Duke University Medical Center; Jakub Tolar, MD, PhD, University of Minnesota; Elsa Shapiro, PhD, University of Minnesota; Simon Jones, MD, Royal Manchester Children's Hospital; Rossella Parini, MD, San Gerardo University Hospital; Marleen Renard, MD, University Hospital Gasthuisberg; Victoria Bordon, MD, Ghent University Hospital; Michele Poe, PhD, University of Pittsburgh; Tom de Koning, MD, PhD, University Medical Center Groningen; Ed Wraith, MD, Royal Manchester Children's Hospital; Maria Escolar, MD, University of Pittsburgh; Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht

83
Allogeneic Stem Cell Transplantation for Children with Sickle Cell Disease Achieves Quality of Life Similar to Normal Children and Is Cost Effective
Staci Arnold, MD, MBA, Columbia University Medical Center; Zhezhen Jin, PhD, Columbia University; Alan Weinberg, MS, Columbia University Medical Center; Jacquelyn Bishop, BS, New York Presbyterian Hospital; Stephen Sands, PsyD, Columbia University Medical Center; Maureen Licursi, PNP, Columbia University Medical Center; Monica Bhatia, MD, Columbia University; Andrew Kung, MD, PhD, Columbia University; Prakash Satwani, MD, Columbia University

84
Low Day 100 Transplant-Related Mortality and Relapse Rate Following Clofarabine in Combination with Cytarabine, Total Body Irradiation and Allogenic Stem Cell Transplantaiton in Children, Adolescents and Young Adults with Poor-Risk Acute Leukemia
Nan Chen, BS, New York Medical College; Kavita Radhakrishnan, University of San Francisco; Jennifer Krajewski, MD, Hackensack University Medical Center; Angela Ricci, Boston Children's Hospital; Mark Geyer, AB, Massachusetts General Hospital, Harvard Medical School; Lauren Harrison, RN, New York Medical College; M Fevzi Ozkaynak, MD, New York Medical College; Alexandra Cheerva, MD, MS, University of Louisville; Julie-An Talano, MD, Children's Hospital of Wisconsin; Theodore B Moore, MD, David Geffen School of Medicine at UCLA; Alfred P. Gillio, MD, HUMC; Mark Walters, MD, Children's Hospital & Research Center, Oakland; Lee Ann Baxter-Lowe, PhD, UCSF; Mitchell S. Cairo, MD, New York Medical College

85
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review
Ram Kalpatthi, MD, Children's Mercy Hospital; Matt Hall, PhD, Children's Hospital Association; Gerald Woods, MD, Children's Mercy Hospital; Jignesh Dalal, MD, Children's Mercy Hospital

87
Progressive Decrease in Mortality of Post-Induction Marrow-Ablative Chemotherapy with Autologous Hematopoetic Cell Rescue for Young Children with Newly-Diagnosed Malignant Central Nervous System Tumors: The “Head Start” I-III (HSI-III) Trials, 1991-2009
Jonathan L. Finlay, MB, ChB, Children's Hospital Los Angeles; Kelley Haley, RN, PNP, Children's Hospital Los Angeles; Laura Vasquez, RN,, Children's Hospital Los Angeles; Girish Dhall, MD, Children's Hospital Los Angeles; Lingyun Ji, MS, Children's Hospital Los Angeles; Richard Sposto, PhD, Children's Hospital Los Angeles; Sharon Gardner, MD, New York University

88
Encouraging Leukemia-Free Survival Rates in 72 Pediatric Acute Lymphoblastic Leukemia (ALL) in CR Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Using a TBI-Free Conditioning Regimen
Amir Ali Hamidieh, MD, Tehran University of Medical Sciences; Maryam Behfar, M.D., Tehran University of Medical Sciences; Leila Sharifi Aliabadi, Tehran University of Medical Sciences; Arash Jalali, Tehran University of Medical Sciences; Ashraf sadat Hosseini, Tehran University of Medical Sciences; Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences